Africa | Novartis

Media Release
Nov 23, 2022
Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria
Featured News
Oct 13, 2022
World Sight Day 2022: Raising awareness on the importance of eye health
Media Release
Jun 23, 2022
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
Story
Jun 17, 2022
Sickle cell screening urged for newborns in Africa
Media Release
Jun 02, 2022
Novartis announces partnership with the American Society of Hematology to fight sickle cell disease in Sub-Saharan Africa
Media Release
Sep 29, 2021
Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria
Media Release
Jan 19, 2021
Novartis and GSK announce collaboration to support scientific research into genetic diversity in Africa
Media Release
Feb 17, 2021
Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease
Media Release
May 18, 2021
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
Media Release
Dec 09, 2019
Novartis global survey uncovers profound and often under-reported effects on sickle cell disease patients
Media Release
Feb 25, 2020
Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis
Media Release
Mar 03, 2020
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa